Abstract:Abstract Background: Fruquintinib is a novel oral small molecule compound discovered and developed by Hutchison MediPharma that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts. This first-in-human study was conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs), safety and tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of fruquintinib. Methods: This phase I study used a 3+3 design for dose-escalation of fruquintinib given once daily continuously (QD) or 3 weeks on and 1 week off in 28-day cycles in patients with solid tumors who had failed standard therapies. Endpoints included safety, PK, and preliminary efficacy measurements. Results: Forty patients were enrolled in 5 dose cohorts of 1-6 mg QD and 2 dose cohorts of 5mg and 6mg 3 wks on/1 wk off, with age 18-70 yr, 40% male, ECOG 0-1 and heavily pretreated cancers. Tumor types included CRC (12), breast (8), NSCLC (7), thyroid (3), gastric (2) and others (8). The most common adverse events (all grades) were hand-foot syndrome (HFS), elevation of serum thyroid stimulating hormone (TSH), stomatitis, hypertension, white blood cell decreased, proteinuria, hoarseness, fatigue, and diarrhea, each observed in ≥ 30% pts. Grade 3/4 AEs were relatively uncommon, with HFS and hypertension the only AEs occurred in ≥ 10% pts (15% for each). Only 6 pts terminated study treatment due to related AEs. 6 DLTs were observed: 2 grade 3 HFS both at 6mg, 1 grade 3 HFS and 1 grade 3 thrombocytopenia with subcutaneous bleeding at 5mg, 1 grade 3 hyperbilirubinemia at 4mg and 1 grade 3 fatigue at 6mg 3wks on/1 wk off. MTD was determined as 4mg QD or 6mg 3wks on/1 wk off. PK analysis showed good and rapid absorption followed by slow terminal elimination with a half-life of approximately 42 hours which was consistent across all dose groups. Both Cmax and AUC exhibited good dose proportionality over the studied dose range with low inter-patient variability following single and multiple doses. 34 patients were evaluable for tumor response, including 13 with confirmed partial response (PRs: 4 NSCLC, 3 CRC, 2 breast, 1 gastric, 1 pNET, 1 glandula submandibularis and 1 nasopharyngeal); and 15 with stable disease (SDs: 14 were 3-9 months). Conclusions: Fruquintinib was well tolerated at doses up to 4mg QD or 6mg 3wks on/1 wk off, and demonstrated excellent pharmacokinetic properties. Impressive clinical activity including durable PR and SD was observed in majority of patients with various heavily pre-treated advanced cancers. These promising results warrant further clinical development of fruquintinib. Citation Format: Jin Li, Junning Cao, Jian Zhang, Zhiyu Chen, Wei Peng, Songhua Fan, Charlie Qi, Yi Gu, Yang Sai, Hua Mu. Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2413. doi:10.1158/1538-7445.AM2013-2413

A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

The irreversible FGFR inhibitor KIN-3248 overcomes FGFR2 kinase domain mutations.

Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations

Discovery of 1-{(3R,4R)-3-[5-Chloro-2-(1-methyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxymethyl]-4-methoxy-pyrrolidin-1-yl}propenone (PF-06459988), A Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

Phase 1 Study of NB003, a Broad-Spectrum KIT/PDGFRα Inhibitor, in Patients with Advanced Gastrointestinal Stromal Tumors (GIST).

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies

Abstract A080: A Phase 1 Study of Single-Agent Pexidartinib in Asian Patients with Advanced Solid Tumors (NCT02734433)

Safety, Pharmacokinetics (PK), and Clinical Efficacy of ICP-723, a Highly Selective Next-Generation Pan-Trk Inhibitor, in Patients with Solid Tumor.

Abstract 1965: 3HP-2827-high selective inhibitor of FGFR2, a best-in-class therapy for FGFR2-driven solid tumors

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models

A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.

A phase I study of a TGF- receptor I kinase inhibitor YL-13027 in patients with advanced solid tumors.

Abstract 2413: Phase I Study of Safety and Pharmacokinetics of Fruquintinib, a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases in Patients with Advanced Solid Tumors.

Phase I Study of Safety and Pharmacokinetics of Fruquintinib, a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases in Patients with Advanced Solid Tumors.

First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.

Abstract CT102: Interim results of a first-in-human, dose escalation and expansion study of PLB-1004, an irreversible inhibitor of exon 20 insertion mutations in patients with non-small cell lung cancer

Abstract CT116: Preclinical antitumor activity and first-in-human phase I study of NB004/GDC-0570, a novel pan-PIM kinase inhibitor, in patients with advanced solid tumors

473P Phase I Study of GFH018, a Small Molecular TGF-βRI Inhibitor, in Patients (pts) with Advanced Solid Tumors

Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial

Abstract CT163: FIT-001: A phase 1 clinical trial of the farnesyl transferase inhibitor KO-2806 alone or as part of combination therapy for advanced solid tumors

Abstract 1968: Discovery of a highly potent and selective FGFR2 inhibitor for FGFR2-driven cancers